Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Gross Profit (2020 - 2025)

Xeris Biopharma Holdings' Gross Profit history spans 6 years, with the latest figure at $74.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 47.88% year-over-year to $74.9 million, compared with a TTM value of $249.3 million through Dec 2025, up 49.95%, and an annual FY2025 reading of $249.3 million, up 49.95% over the prior year.
  • Gross Profit for Q4 2025 was $74.9 million at Xeris Biopharma Holdings, up from $63.4 million in the prior quarter.
  • The five-year high for Gross Profit was $74.9 million in Q4 2025, with the low at $5.5 million in Q2 2021.
  • Average Gross Profit over 5 years is $33.7 million, with a median of $32.6 million recorded in 2023.
  • Year-over-year, Gross Profit soared 321.08% in 2021 and then grew 1.39% in 2024.
  • Tracing XERS's Gross Profit over 5 years: stood at $16.5 million in 2021, then skyrocketed by 62.35% to $26.9 million in 2022, then skyrocketed by 37.12% to $36.8 million in 2023, then soared by 37.48% to $50.6 million in 2024, then soared by 47.88% to $74.9 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Gross Profit are $74.9 million (Q4 2025), $63.4 million (Q3 2025), and $59.6 million (Q2 2025).